Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial

INTRODUCTION: Levodopa remains the cornerstone treatment for Parkinson’s disease (PD) but its use is associated with the development of ‘wearing-off’ fluctuations and other motor and non-motor complications over time. Adding a catechol-O-methyltransferase (COMT) inhibitor to levodopa/dopa decarboxyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Joaquim J., Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio, Antonini, Angelo, Moreira, Joana, Pereira, Ana, Rocha, José-Francisco, Soares-da-Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338182/
https://www.ncbi.nlm.nih.gov/pubmed/35705887
http://dx.doi.org/10.1007/s40120-022-00371-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338182/
https://www.ncbi.nlm.nih.gov/pubmed/35705887
http://dx.doi.org/10.1007/s40120-022-00371-7

Ejemplares similares